ischemic stroke

[GNT Pharma Inc. (BusinessWire, Inc.)] GNT Pharma Inc. reported that the Korea Ministry of Food and Drug Safety has approved the Investigational New Drug Application for a phase III study of nelonemdaz for acute ischemic stroke patients.

[Stem Cells International] The authors provide an overview of recent scientific reports concerning novel strategies that promote MSC transplantation as an effective therapeutic approach, including physical approaches, chemical agents, traditional Chinese medicines and extracts, and genetic modification.

[Cell Death & Disease] Through a genome-wide small RNA sequencing, researchers identified several tRNA-derived fragments and piwi-interacting RNA species were enriched in glutamate-induced neuronal necrosis in rat primary neuron cultures, and this enrichment was dependent on the H3K4me3 increase.

[Athersys, Inc.] Athersys, Inc. announced that its partner, HEALIOS K.K., has completed enrollment in its TREASURE study in Japan, evaluating MultiStem® cell therapy treatment in patients who have suffered an ischemic stroke.

[Acta Pharmacologica Sinica] Researchers showed that CKLF1 was significantly up-regulated in cultured rat cortical neurons subjected to oxygen-glucose deprivation/reoxygenation (ODG/R) injury, but not in cultured rat microglia, astrocytes and oligodendrocytes.

[Scientific Reports] Investigators demonstrated that, in an in vitro setting, MAPC cells increase Treg frequencies by promoting Treg proliferation and CD4+ T cell differentiation into Tregs.